Abstract
Protection of the brain is strengthened by active transport and ABC transporters. P-glycoprotein (P-gp) at the blood-brain barrier (BBB) functions as an active efflux pump by extruding a substrate from the brain, which is important for maintaining loco-regional homeostasis in the brain and protection against toxic compounds. Importantly, dysfunctional BBB P-gp transport is postulated as an important factor contributing to accumulation of aggregated protein in neurodegenerative disorders such as Alzheimers disease (AD) and Parkinsons disease (PD). Furthermore, P-gp is a major factor in mediating resistance to brain entry of numerous exogenous compounds, including toxins that can be involved in PD pathogenesis. This review highlights the role of altered P-gp function in the pathogenesis and progression of neurodegenerative disease. Also the implications of alterations in P-gp function for the treatment of these diseases are discussed.
Keywords: Blood-brain barrier, P-glycoprotein, [11C]-verapamil PET, Parkinson, Alzheimer, Microglia, pesticides, olfactory neurons, progressive supranuclear palsy (PSP), mutation
Current Pharmaceutical Design
Title: Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
Volume: 17 Issue: 26
Author(s): A.L. Bartels
Affiliation:
Keywords: Blood-brain barrier, P-glycoprotein, [11C]-verapamil PET, Parkinson, Alzheimer, Microglia, pesticides, olfactory neurons, progressive supranuclear palsy (PSP), mutation
Abstract: Protection of the brain is strengthened by active transport and ABC transporters. P-glycoprotein (P-gp) at the blood-brain barrier (BBB) functions as an active efflux pump by extruding a substrate from the brain, which is important for maintaining loco-regional homeostasis in the brain and protection against toxic compounds. Importantly, dysfunctional BBB P-gp transport is postulated as an important factor contributing to accumulation of aggregated protein in neurodegenerative disorders such as Alzheimers disease (AD) and Parkinsons disease (PD). Furthermore, P-gp is a major factor in mediating resistance to brain entry of numerous exogenous compounds, including toxins that can be involved in PD pathogenesis. This review highlights the role of altered P-gp function in the pathogenesis and progression of neurodegenerative disease. Also the implications of alterations in P-gp function for the treatment of these diseases are discussed.
Export Options
About this article
Cite this article as:
Bartels A.L., Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease, Current Pharmaceutical Design 2011; 17 (26) . https://dx.doi.org/10.2174/138161211797440122
DOI https://dx.doi.org/10.2174/138161211797440122 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Recent Advances of Biology and Medicinal Chemistry of Prion Protein and Prions: On the Road to Therapeutics)
Current Topics in Medicinal Chemistry GPCR Drug Discovery: Novel Ligands for CNS Receptors
Recent Patents on CNS Drug Discovery (Discontinued) The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Current Medicinal Chemistry Effects of Transition Metals in the Conversion Mechanism of Prion Protein and in the Pathogenesis of Prion Diseases
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Importance of P-gp PET Imaging in Pharmacology
Current Pharmaceutical Design GSK-3 Inhibitors: Discoveries and Developments
Current Medicinal Chemistry GSK-3 Inhibitors: A New Class of Drugs for Alzheimer’s Disease Treatment
Current Drug Targets Application of Polymeric Nanoparticles for CNS Targeted Zinc Delivery In Vivo
CNS & Neurological Disorders - Drug Targets Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions
Current Topics in Medicinal Chemistry The Identification and Characterization of Excitotoxic Nerve-endings in Alzheimer Disease
Current Alzheimer Research Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) The Renin-Angiotensin System in Huntington’s Disease: Villain or Hero?
Protein & Peptide Letters Nanoparticles, Neurotoxicity and Neurodegenerative Diseases
Current Drug Metabolism Recent Advancements in Liposome-Based Strategies for Effective Drug Delivery to the Brain
Current Medicinal Chemistry Exploring the Role of Aggregated Proteomes in the Pathogenesis of Alzheimer’s Disease
Current Protein & Peptide Science Glaucoma and Aging
Current Aging Science Tryptophan Catabolites and Migraine
Current Pharmaceutical Design “Tripping out” with the TRP Superfamily and TRPV1 for Novel Neuroprotection
Current Neurovascular Research Possible Mechanisms of Action of NSAIDs and Related Compounds that Modulate γ - Secretase Cleavage
Current Topics in Medicinal Chemistry